Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 9/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496454 | 0.84 | ABCB1 (0.48) | ABCB1ABCG2MEN1KMT2A | |
| SCHEMBL6496463 | 0.84 | ABCB1 (0.48) | ABCB1ABCG2MEN1KMT2A | |
| SCHEMBL6501779 | 0.75 | DRD2 (0.46) | ABCB1ABCG2PRMT5WDR77 | |
| SCHEMBL6496773 | 0.75 | ABCB1 (0.40) | ABCB1ABCG2PRMT5WDR77 | |
| SCHEMBL6489547 | 0.73 | ABCB1 (0.53) | ABCB1ABCG2OPRM1OPRD1OPRK1 | |
| SCHEMBL2844019 | 0.72 | SIGMAR1 (0.47) | ABCB1ABCG2KDM4EALOX15OPRM1 | |
| SCHEMBL21239023 | 0.71 | HDAC3 (0.53) | KDM4EALOX15PRMT5WDR77MEN1 | |
| SCHEMBL1075208 | 0.71 | MAOA (0.49) | — | |
| SCHEMBL27583377 | 0.71 | NR3C2 (0.46) | KDM4EMEN1KMT2A | |
| SCHEMBL6967685 | 0.71 | PRMT5 (0.47) | ABCB1KDM4EPRMT5WDR77MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | ABCB1 699/4885ABCG2 436/4885KDM4E 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.